Bio

Paul Teitelbaum has over 25 years of healthcare investment banking, corporate development, and management experience, with a particular focus on medical technology and life sciences. He has completed numerous M&A, financing, and strategic partnership transactions for private and public companies. Prior to joining England & Company in 2015, Mr. Teitelbaum was Managing Director of the Healthcare Investment Banking Group at Mesirow Financial. He also served as a Managing Director of Healthcare Investment Banking at Landmark Ventures, and as a healthcare investment banker at Robertson Stephens and Burnham Securities. Previously, Mr. Teitelbaum held corporate development and disease management roles at Schering-Plough (now Merck & Co., Inc.) and Wyeth-Lederle (now Pfizer, Inc.). Mr. Teitelbaum received his BA in Biology summa cum laude from the University of Pennsylvania and his MBA in Finance from the Wharton School of the University of Pennsylvania.